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ABSTRACT 
Objective: Microbial resistance to currently marketed drugs is a serious problem worldwide and there is a vital need to develop novel antibiotics. 
Enoyl-ACP reductase (FabI) is essential for fatty acid biosynthesis and hence serves as an appealing target for antibacterials against methicillin 
resistant S. aureus. The present study focuses on the synthesis, antibacterial and saFab1 docking studies of three new series of quinoline derivatives: 
5-[(quinolin-8-yloxy) methyl]-1,3,4-oxadiazole-2(3H)-thiones, N-(2,5-dimethyl-1H-pyrrol-1-yl)-2oxyacetamides and 
Methods: Three different substituted hydrazides were synthesized from substituted quinolinols. These hydrazides were allowed to undergo further 
reactions with carbon disulphide, 2,5-hexanedione and ethyl acetoacetate respectively to prepare 1,3,4-oxadiazole-2-thiones, N-substituted pyrrole 
acetamides and pyrazol-3-ones. The synthesized hydrazide derivatives were subjected to antimicrobial studies against Staphylococcus aureus. 
Docking studies were carried out using enoyl-ACP reductase crystal structure complexed with NADPH.  
2-(oxyacetyl)-5-methyl-2,4-
dihydro-3H-pyrazol-3-ones with integrated ether linkages.  
Results: 5-{[(2-methylquinolin-8-yl) oxy] methyl}-1, 3, 4-oxadiazole-2(3H)-thione (2b) with a methyl substituent on the quinoline ring was found 
to display significant antibacterial potential against S. aureus. Good binding interactions were observed in subsequent docking studies via formation 
of Fab1-NAD+
Conclusion: 1, 3, 4-oxadiazole-2(3H)-thione (2b) was found to exhibit promising antibacterial potential against S. aureus. 
-2b ternary complex through hydrogen bonding and stacking interactions. 
Keywords: Oxadiazole, Antibacterial, saFab1, Triclosan.  
 
INTRODUCTION 
Antibiotics have turned the tide in terms of the treatment of various 
types of infectious diseases. But the evolution of antibiotic-resistant 
strains is of principally severe concern due to the biochemical 
fickleness of several bacteria and the over use of many of these 
antibiotics. Multidrug resistant bacteria have become a major public 
health crisis because existing antibiotics are no longer effective in 
many cases. Considering the rapid advance of multidrug resistance 
to the existing variety of marketed antibiotics, new approaches are 
immediately needed. In recent times very few novel antibiotics have 
been reported. Hence it is essential to discover antibiotics that act 
through the disruption of a novel target. 
Staphylococcus aureus is a dangerous gram-positive pathogen that is 
readily transferred to immune-compromised patients [1, 2]. 
Methicillin-resistant S. aureus (MRSA) strains are unfortunately 
widespread [3] and the well-recognized resistance among S. aureus 
strains against penicillins is apparently totally because of the 
production of an inducible β-lactamase. The severity of this problem 
has been further added by the fact that antibiotics that have usually 
been drugs of last resort like vancomycin are becoming the first line 
of treatment of resistant infections [4, 5]. Thus, there is an urgent 
requirement for newer antibiotics to combat these continually 
adapting pathogens.  
One strategy that targets the bacterial cell envelope involves the 
selective inhibition of the type II fatty acid biosynthesis pathway 
(FAS II) which consists of individual mono functional enzymes that 
are responsible for the endogenous production of lipids to be 
incorporated into the bacterial cell membrane. The final reduction in 
this pathway is catalyzed by the NAD (P) H-dependant trans-2-
enoyl-ACP reductase (FabI), which plays a vital regulatory role. The 
S. aureus enoyl-ACP reductase (saFabI) is the only known FabI which 
has a determinant role in completing cycles of elongation in type II 
fatty acid synthase systems with a clear preference for NADPH that 
has garnered the most attention as an antibacterial target. The 
clinical success of FabI inhibitors, such as isoniazid and triclosan 
validates this enzyme as a striking dug target [6, 7]. Triclosan binds 
at the FabI active site and the replacement of the ether linkage in 
triclosan by a carbon bridge prevents the formation of a stable FabI-
NAD (P)1-drug ternary complex which is a key factor for the 
antibacterial activity of FabI inhibitors.  
The oxadiazole group has been demonstrated to bear an important 
application in medicinal chemistry with anticancer, 
antiinflammatory, antituberculosis, antimalarial and anti 
schistosomiasis properties [8]. A number of therapeutic agents such 
as HIV integrase inhibitor raltagravir [9], nitrofuran antibacterial 
furamizole [10], a potent peptide deformylase inhibitor BB-83698 
[11], antihypertensive agents tiodazosin [12] and nesapidil 13 are 
based on 1,3,4-oxadiazole moiety. Pyrrole derivatives represent a 
class of compounds of great importance in heterocyclic chemistry 
with biological importance [14, 15]. The presence of pyrazole moiety 
in organic molecules has proved to play ubiquitous role in the field 
of pharmaceutical chemistry [16-22]. In the present study, we 
explore few quinoline derivatives with an incorporated ether 
linkage for their antibacterial and Sa-FabI inhibitory potential. 
MATERIALS AND METHODS 
General 
Thin layer chromatography was performed using pre coated 
aluminium sheets with Aluchrosep silica Gel 60/UV254 and spots 
were visualized in UV chamber. The elemental analysis of the newly 
synthesized compounds was carried out in Flash thermo 1112 series 
CHN analyser.  
The IR spectra in KBr pellets and 1H-NMR and 13C-NMR spectra with 
TMS as internal standard and DMSO-d6 as solvent were recorded in 
a Schimadzu FTIR 8400S spectrophotometer and 400 MHz AV500 
NMR spectrometer respectively. The mass spectrum was taken in a 
Schimadzu GCMS-QP5050 mass spectrometer. Melting points were 
determined by open capillary method and were uncorrected. 
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Synthesis 
Three different substituted hydrazides were synthesized from 
substituted quinolinols by multistep reactions. Equimolar 
quantitities of substituted quinolinols and ethylchloroacetate was 
allowed to react in the presence of potassium carbonate for 18 h in 
dry acetone medium to give the ester. The ester obtained was 
further refluxed with hydrazine hydrate to give the corresponding 
hydrazides. The hydrazides were allowed to undergo further 
reactions to prepare 1, 3, 4-oxadiazole-2-thiones, N-substituted 
pyrrole acetamides and pyrazol-3-ones (Scheme-1). 
Synthesis of 5-[(substitutedquinolin-8-yloxy) methyl]-1, 3, 4-
oxadiazole-2(3H)-thiones [2a-c] 
About 0.0038 mole of hydrazide was dissolved in a solution of 0.006 
mol of KOH in 2 mL of water and 20 mL ethanol. To the above 
reaction mixture 2 mL carbon disulphide was added with stirring 
and refluxed for 8 h. Solvents were removed and the residue 
obtained was treated with water, filtered, dried and recrystallized 
from ethanol. 
5-[(quinolin-8-yloxy) methyl]-1, 3, 4-oxadiazole-2(3H)-thione [2a] 
Cream solid (53 %) m. p. 260 °C; Rf = 0.225; IR (KBr) [cm-1]: 3402 
(N-H str.), 3055 (Ar. C-H str.), 1604 (C=N str.), 1180 (C=S str.), 1581 
(Ar. C=C str.), 1257 (Ar. C-O-C asym. str.), 1103 (Ar. C-O-C sym. str.); 
1H NMR [ppm] DMSO-d6, 400 MHz: 5.23 (s, 2H, OCH2), 7.31-8.21 
(6H, Ar. H), 11.21 (brs, N-H); 13C NMR, 400 MHz, DMSO-d6 δ = 87.15, 
114.90, 121.53, 123.72, 124.85, 128.24, 129.58, 135.67, 142.33, 
142.24, 144.27, 155.20; MS (FAB+): m/z (%): 259 M+(100 %); Anal. 
Calcd. For C12H9N3O2
 
S: C, 55.60; H, 3.47; N, 16.22; found: C, 55.78; 



























Comp. No. R 
1a, 2a, 3a, 4a 8-quinolinyl 
1b, 2b, 3b, 4b 2-methyl-8-quinolinyl 
1c, 2c, 3c, 4c 5,7-dichloro-8-quinolinyl 
 
 




Cream solid (63 %) m. p. 264 °C; Rf = 0.61; IR (KBr) [cm-1]: 3456 (N-
H str.), 3062 (Ar. C-H str.), 2916 (CH3 asym. str.), 2831 (CH3 sym. 
str.), 1612 (C=N str.), 1180 (C=S str.), 1573 (Ar. C=C str.), 1226 (Ar. 
C-O-C asym. str.), 1110 (Ar. C-O-C sym. str.); 1H NMR [ppm] DMSO-
d6, 400 MHz: 2.66 (s, 3H, CH3), 5.24 (s, 2H, OCH2), 7.29-8.21 (5H, Ar. 
H), 11.21 (brs, N-H); 13C NMR, 400 MHz, DMSO-d6 δ = 20.03, 87.35, 
115.29, 121.65, 122.94, 123.43, 128.24, 130.88, 136.50, 142.58, 
144.67, 152.63, 153.29; MS (FAB+): m/z (%): 273 M+(100 %); Anal. 
Calcd. For C13H11N3O2S: C, 57.14; H, 4.03; N, 15.38; found: C, 57.35; 
H, 4.04; N, 15.41. 
5-{[(5,7-dichloro-2-methylquinolin-8-yl)oxy]methyl}-1,3,4-
oxadiazole-2(3H)-thione [2c] 
Cream solid (66 %) m. p. 270 °C; R f  = 0.48; IR (KBr) [cm-1]: 3421 
(N-H str.), 3139 (Ar. C-H str.), 1635 (C=N str.), 1184 (C=S str.), 
1581 (Ar. C=C str.), 1218 (Ar. C-O-C asym. str.), 1103 (Ar. C-O-C 
sym. str.); 1H NMR [ppm] DMSO-d6, 400 MHz: 5.29 (s, 2H, OCH 2), 
7.45-8.29 (4H, Ar. H), 11.22 (brs, N-H); 13C NMR, 400 MHz, DMSO-
d6 δ = 87.24, 121.93, 123.35, 129.03, 129.58, 130.43, 135.75, 
138.18, 142.47, 144.25, 153.65, 154.28; MS (FAB+): m/z (%): 328 
M+(100 %); Anal. Calcd. For C12H7N 3O 2SCl2: C, 43.90; H, 2.13; N, 
12.80; found: C, 44.05; H, 2.14; N, 12.84. 
Synthesis of N-(2,5-dimethyl-1H-pyrrol-1-yl)-2 substitutedoxy 
acetamides [3a-c] 
About 0.0038 mol hydrazide in 10 ml ethanol was added to a 
mixture of 0.006 mol of acetonyl acetone and 1 mL glacial acetic 
acid. The reaction mixture was refluxed for 4 h, concentrated to half 
its volume and poured into 50 g crushed ice. Solid separated was 
filtered, washed with water and recrystallized from ethanol. 
N-(2,5-dimethyl-1H-pyrrol-1-yl)-2-(8-quinolinoloxy)acetamide [3a] 
White solid (66 %) m. p. 112 °C; Rf = 0.46; IR (KBr) [cm-1]: 3517 (N-
H str.), 2916 (CH3 asym. str.), 2846 (CH3 sym. str.), 1689 (C=O str.), 
1512 (Ar. C-C str.), 1249 (C-O-C asym. str.), 1118 (C-O-C sym. str.); 
1H NMR [ppm] DMSO-d6, 400MHz: 1.95 (6H, CH3), 5.07 (s, 2H, 
OCH2), 5.63 (s, 2H, pyrrole), 7.31-8.89 (6H, Ar. H), 11.18 (s, N-H); 13C 
NMR, 400 MHz, DMSO-d6 δ = 19.96, 86.72, 93.90, 121.02, 123.14, 
128.96, 129.35, 130.31, 132.55, 135.29, 138.20, 142.24, 153.38, 
172.64; MS (FAB+): m/z (%): 295 M+(100 %); Anal. Calcd. For 




White solid (72 %); m. p. 108-110 °C; Rf = 0.48; IR (KBr) [cm-1]: 
3521 (N-H str.), 2908 (CH3 asym. str.), 2854 (CH3 sym. str.), 1695 
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(C=O str.), 1604 (Ar. C-C str.), 1257 (C-O-C asym. str.), 1106 (C-O-C 
sym. str.); 1H NMR [ppm] DMSO-d6, 400MHz: 1.94 (s, 6H, CH3), 2.61 
(s, 3H, CH3), 5.09 (s, 2H, OCH2), 5.64 (s, 2H, pyrrole), 7.33-8.89 (5H, 
Ar. H), 11.19 (s, N-H); 13C NMR, 400 MHz, DMSO-d6 δ = 19.82, 20.09, 
87.03, 93.81, 114.57, 121.51, 121.89, 123.35, 128.20, 128.22, 129.55, 
132.62, 133.04, 137.50, 143.09, 172.73; MS (FAB+): m/z (%): 309 
M+(100 %); Anal. Calcd. For C18H19N3O2: C, 69.90; H, 6.15; N, 13.59; 
found: C, 70.17; H, 6.16; N, 13.65.  
N-(2,5-dimethyl-1H-pyrrol-1-yl)-2-(5,7-dichloro-8-quinolinoloxy) 
acetamide [3c] 
Yellowish brown solid (62 %); m. p. 158-160 °C; Rf = 0.71; IR (KBr) 
[cm-1]: 3509 (N-H str.), 2931 (CH3 asym. str.), 2868 (CH3 sym. str.), 
1766 (C=O str.), 1581 (Ar. C-C str.), 1266 (C-O-C asym. str.), 1103 (C-
O-C sym. str.); 1H NMR [ppm] DMSO-d6, 400MHz: 1.95 (s, 6H, CH3), 
5.09 (s, 2H, OCH2), 5.64 (s, 2H, pyrrole), 7.31-8.79 (4H, Ar. H), 11.21 
(s, N-H); 13C NMR, 400 MHz, DMSO-d6 δ = 19.98, 87.12, 93.97, 
121.82, 123.32, 129.05, 129.52, 130.44, 132.65, 135.71, 138.25, 
142.37, 153.68, 172.75; MS (FAB+): m/z (%): 364 M+(100 %); Anal. 
Calcd. For C17H15N3O2Cl2: C, 56.04; H, 4.12; N, 11.54; found: C, 
56.23; H, 4.13; N, 11.58.  
Synthesis of 2-(substitutedoxyacetyl)-5-methyl-2,4-dihydro-3H-
pyrazol-3-ones [4a-c] 
About 0.0038 mol hydrazide was refluxed with 0.0038 mol of ethyl 
acetoacetate for 1 h with stirring. The resultant solution was allowed 
to cool to room temperature, washed thoroughly with ether to 




White solid (54 %); m. p. 156-158 °C; Rf = 0.5; IR (KBr) [cm-1]: 
3155(Ar. C-H str.), 2977 (C-H asym. Str.), 2916 (C-H sym. str.), 1749, 
1704 (C=O str.), 1242 (C-O-C asym. str.), 1118 (C-O-C sym. str.); 1H 
NMR [ppm] DMSO-d6, 400MHz: 1.85 (s, 3H, CH3), 5.10 (s, 2H, OCH2), 
5.54 (s, 2H, pyrrole), 7.21-8.68 (6H, Ar. H); 13C NMR, 400 MHz, 
DMSO-d6) δ = 19.82, 46.00, 71.86, 117.76, 121.22, 125.1, 129.66, 
130.78, 139.13, 142.02, 151.76, 155.5, 159.66, 172.70, 173.42; MS 
(FAB+): m/z (%): 283 M+(100 %); Anal. Calcd. For C15H13N3O3: C, 
63.60; H, 4.59; N, 14.84; found: C, 63.84; H, 4.60; N, 14.89.  
5-methyl-2-{[(2-methylquinolin-8-yl) oxy] acetyl}-2,4-dihydro-3H-
pyrazol-3-one [4b] 
Cream solid (84 %); m. p. 138-140 °C; Rf = 0.44; IR (KBr) [cm-1]: 3147 
(Ar. C-H str.), 2977 (C-H asym. Str.), 2916 (C-H sym. str.), 1757, 1705 
(C=O str.), 1250 (C-O-C asym. str.), 1119 (C-O-C sym. str.); 1H NMR [ppm] 
DMSO-d6, 400MHz: 1.86 (s, 3H, CH3), 2.33 (s, 3H, CH3), 5.12 (s, 2H, 
OCH2), 5.55 (s, 2H, pyrrole), 7.33-8.68 (5H, Ar. H); 13C NMR, 400 MHz, 
DMSO-d6 δ = 19.82, 27.36, 45.89, 71.66, 117.36, 121.12, 126.06, 129.68, 
130.58, 139, 142.09, 155.5, 159.61, 163.06, 172.79, 173.36; MS (FAB+): 
m/z (%): 297 M+(100 %); Anal. Calcd. For C16H15N3O3: C, 60.61; H, 5.05; 
N, 14.14; found: C, 60.81; H, 5.06; N, 14.20.  
2-{[(5,7-dichloroquinolin-8-yl)oxy]acetyl}-5-methyl-2,4-
dihydro-3H-pyrazol-3-one [4c] 
Cream solid (68 %); m. p.120-124 °C; Rf = 0.46; IR (KBr) [cm-1]: 
3139 (Ar. C-H str.), 2985 (C-H asym. Str.), 2870 (C-H sym. str.), 1748, 
1698 (C=O str.), 1296 (C-O-C asym. str.), 1103 (C-O-C sym. str.); 1H 
NMR [ppm] DMSO-d6, 400MHz: 1.86 (s, 3H, CH3), 5.18 (s, 2H, OCH2), 
5.54 (s, 2H, pyrrole), 7.36-8.67 (4H, Ar. H); 13C NMR, 400 MHz, 
DMSO-d6) δ = 19.86, 46.09, 71.75, 125.17, 125.94, 128.34, 132.80, 
133.26, 136.24, 142.02, 151.76, 156.29, 159.66, 172.7, 173.40; MS 
(FAB+): m/z (%): 352 M+(100 %); Anal. Calcd. For C15H11N3O3Cl2: C, 
51.14; H, 3.13; N, 11.93; found: C, 51.25; H, 3.14; N, 11.96.  
Antimicrobial studies 
The antimicrobial activity of synthesized compounds was examined 
by Disc Diffusion Method. Nutrient agar media was prepared and 
plated on petriplates. Plates were inoculated by swab culturing 
using stock culture. Different discs were dipped in the solution of 
hydrazide derivatives and placed in inoculated plates using sterile 
forceps and were gently pressed. Plates were further incubated for 
24 h at 37 °C for Gram+ve Staphylococcus aureus. The experiments 
were performed in duplicates. After incubation, diameter of an 
inhibition zone was measured. Tetracycline (500 µg/ml) was used 
as the standard drug. 
Docking studies 
The enoyl-ACP reductase crystal structure complexed with NADPH 
(Dihydro-Nicotinamide-Adenine-Dinucleotide Phosphate) with a 
corresponding entry code 4CUZ was recovered from the PDB 
database (www. pdb. org). Surflex dock module of sybyl ver 1.7 was 
used (Tripos Inc. St. Louis, USA) and protomol were generated based 
on already complexed ligand residues (i.e.1-(3-amino-2-
methylbenzyl)-4-hexylpyridine-2(1H)-one) for carrying out docking 
studies. The proprietary software is licensed to Manipal Institute of 
Technology, Manipal University, India. The best favorable 
conformation in terms of highest docking score was chosen [23]. 
RESULTS AND DISCUSSION 
The formation of cyclized product 5-[(substitutedquinolin-8-
yloxy)methyl]-1,3,4-oxadiazole-2(3H)-thiones (2a-c) were 
confirmed by the IR absorption peaks observed at 1604 cm-1 and 
1180 cm-1 due to C=N and C=S stretching vibrations. The 1HNMR 
spectra showed a singlet at 5.23 ppm corresponding to OCH2 
protons and a broad peak at 11.21 ppm due to proton attached to 
nitrogen. The carbonyl stretch in the IR spectra of compounds 3a-c 
was observed at around 1690 cm-1.  
The formation of pyrrole ring was confirmed by the singlet observed 
at 5.6 ppm in the 1HNMR spectra. The six identical protons of the 
methyl groups attached to the pyrrole ring were found to resonate at 
1.9 ppm. The formation of pyrazol-3-ones was confirmed by the 
appearance of two carbonyl stretching vibrations in the IR spectra at 
1700 cm-1 and 1750 cm-1. The 1HNMR spectra displayed the three 
methyl protons and the 2 protons in the pyrrole ring as singlets at 
1.8 and 5.5 ppm respectively. The 13
All the oxadiazole thione derivatives (2a-c) were found to show good 
antibacterial activity against S. aureus. The compound 2b with 
methyl substituent on the quinoline ring was found to be the most 
sensitive among the three oxadiazole thiones. Neither the pyrrole 
nor pyrazolone derivatives, exhibited any sensitivity towards the 
bacterial strain studied. The results of antimicrobial studies of the 
hydrazide derivatives expressed as mean value of the duplicates 
against S. aureus are given in table 1. 
 C NMR spectra of all the 
synthesized compounds accounted for the respective number of 
carbon atoms. The mass spectra of the compounds were in 
agreement with the molecular weights of the compounds. 
 
Table 1: Zone of inhibition and docking scores of quinoline derivatives 
Comp. No. Zone of inhibitiona 4cuz(FabI)-docking score  (mm) Comp. No. Zone of inhibition (mm) 4cuz(FabI)-docking score 
2a 16 5.45 3c - 5.58 
2b 20 6.67 4a - - 
2c 11 6.34 4b - - 
3a - 6.34 4c - - 
3b - 6.58 Tetracycline 37 - 
aInhibition zone expressed as mean of two replicas 
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The similarities in the structures of synthesized compounds and 
triclosan and its proposed mechanisms of action prompted us to 
determine whether the oxadiazoles were also FabI inhibitors. To 
investigate the suitability of saFabI as a drug target, we have 
structurally characterized this enzyme with respect to inhibitor 
binding and conformational flexibility and further compared with 
triclosan-saFabI complex structure. The results of the docking 
studies are presented in table 1. The docked conformer of 2b is 
depicted in fig. 1A. Triclosan is a particularly effective FabI inhibitor 
due to the slow formation of a stable, ternary FabI-NAD+-triclosan 
ternary complex, and this property of triclosan is responsible for its 
antibacterial activity through the formation of H-bond between 
oxygen attached to quinoline ring of 2b and NDP1258 of NADPH. 
The two nitrogen atoms of oxadiazole ring of 2b were also found to 
engage in H-bonds with Tyrosine 157 which is much similar to the 
sandwiched binding mode between triclosan, the protein and the 
cofactor. Hydrogen bond network and stacking interactions from the 
bridge that connects triclosan, protein and NAD+ [24]. Compound 2b 
also demonstrates the formation of ternary complexes with FabI. The 
ternary FabI-NAD+
  
-2b complex formation is represented in fig. 1B.
 
Fig. 1: A) Docked conformer of 2b with the active residue of Fab1 and the substrate NADPH, B) FabI-NAD+
 
-2b complex formation; Red-
ligand, Green-Tyrosine 157 of Fab1 and Purple-NADPH 
The ether linkage in tri closan is a structural feature that is essential 
for the formation of the inhibitory ternary complex. The substitution 
of a carbon bridge for the ether oxygen in triclosan results in a 
compound that cannot orient itself to optimally participate in this 
network. This is most likely attributed to the different angle of the 
carbon bridge compared with the ether bridge, preventing the 
molecule from forming hydrogen bond connections and the stacking 
interactions with NAD+ [25]. It is also proposed that the ether oxygen 
of triclosan is part of a hydrogen bond network that also includes 
the hydroxyl groups of Tyr-156, triclosan, and the NAD+
CONCLUSION 
ribose [26]. 
Thus, the presence of the ether oxygen is clearly important in 
promoting tight drug binding and the ensuing conformational 
change that leads to essentially irreversible FabI inhibition and 
potent antibacterial activity. Thus the presence of ether linkage and 
the ability to form ternary bonding might have made 2b the most 
potential antibacterial agent among all the compounds studied.  
In the present study three new series of hydrazide derivatives 
incorporating bioactive quinoline moiety were synthesized and 
were characterized by spectral techniques. Antimicrobial activity of 
oxadiazole thione, pyrrole and pyrazolone derivatives of hydrazides 
was studied by disc diffusion method. All the oxadiazole thione 
derivatives showed good antibacterial activity against S. aureus.  
Increased opportunities for hydrogen bond formation between the 
nitrogens and oxygen and the protein is one possible explanation for 
understanding the potency of 2b as a FabI inhibitor. Molecular 
modeling of the energy-minimized docked FabI-NAD1-2b structure 
indicated the formation of ternary bond formation. The ether linkage 
is an essential feature for ternary complex formation and ensuing 
conformational changes that can promote its interaction with FabI 
with potent antibacterial activity. Oxygen bridge in 2b which is 
critical to the formation of a ternary complex, similar to triclosan 
might have added to the structural features that determine 
inhibitory activity. 
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